Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Pharmacol ; 21(7): 668-75, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20729714

ABSTRACT

Olanzapine and highly palatable diets can alter metabolism and brain function. We investigated the interaction of chronic treatment (4 months) with olanzapine and a cafeteria diet on metabolic parameters, memory tasks (spatial and aversive), the elevated plus maze and locomotor activity induced by d-amphetamine. Male Wistar rats were separated into the following groups: standard diet vehicle, standard diet and olanzapine, cafeteria diet vehicle and cafeteria diet and olanzapine. Olanzapine was administered in the drinking water (approximately 1.5 mg/kg/day), and after 3 days of treatment, the rats exhibited an expected anxiolytic effect and reduced amphetamine-induced hyperlocomotion. After 4 months of treatment, cafeteria diet vehicle and cafeteria diet olanzapine rats exhibited an increased body weight and heavier fat pads compared with the standard diet groups. Olanzapine increased only the epididymal and mesenteric fat pads. The cafeteria diet and olanzapine group showed greater glucose intolerance compared with all other groups. The cafeteria diet altered the effects of chronic olanzapine on the performance in the water maze and inhibitory avoidance tasks. Chronic olanzapine treatment failed to affect amphetamine-induced locomotion and to produce anxiolytic effects in the elevated plus maze task, regardless of the diet. Our results suggest that chronic olanzapine caused an increase in fat pads, which is putatively involved in the etiology of many metabolic diseases. Rats on the cafeteria diet were overweight and exhibited glucose intolerance. We did not observe these effects with olanzapine treatment with the standard diet. Moreover, the chronic treatment regimen caused tolerance to the antipsychotic and anxiolytic effects of olanzapine and seemed to potentiate some of the metabolic effects of the cafeteria diet. The cafeteria diet also modified the effects of chronic treatment with olanzapine on cognitive tasks, which may represent an undesirable effect of poor diets in psychiatric patients.


Subject(s)
Behavior, Animal , Benzodiazepines , Fast Foods , Glucose Intolerance , Obesity , Amphetamine/pharmacology , Animals , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Behavior, Animal/drug effects , Benzodiazepines/administration & dosage , Benzodiazepines/adverse effects , Diet/psychology , Dietary Fats/adverse effects , Eating/drug effects , Eating/psychology , Fast Foods/adverse effects , Glucose Intolerance/etiology , Glucose Intolerance/metabolism , Humans , Male , Maze Learning , Motor Activity/drug effects , Obesity/etiology , Obesity/metabolism , Olanzapine , Rats , Rats, Wistar
2.
J Card Fail ; 13(10): 850-4, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18068619

ABSTRACT

BACKGROUND: The S100B protein is considered a biochemical marker for brain injuries. However, our group demonstrated that the isolated rat heart releases S100B. In this study, we investigated the serum levels of S100B in dilated cardiomyopathy (DCM) patients to evaluate its levels in heart disease. METHODS AND RESULTS: We selected DCM patients, excluding any condition that could influence S100B serum levels. Control individuals were sex and age matched. Both groups were submitted to clinical evaluation and echocardiography. We measured the S100B and NT-proBNP serum levels (expressed as median [interquartile range]). NT-proBNP levels in patients group (1462 pg/mL [426-3591]) were higher than in controls (35 pg/mL [29-55]), P < .001. S100B serum levels were higher in patients group (0.051 microg/L [0.022-0.144]) than in controls (0.017 microg/L [0.003-0.036]), P = .009. Additionally, we found a positive correlation between S100B and NT-proBNP serum levels only in patients group (Spearman's coefficient r = 0.534; P = .013). CONCLUSIONS: Although we cannot rule out the influence of S100B from brain, the positive correlation between S100B and NT-proBNP levels in DCM patients points to the myocardium as the main source for the rise in S100B serum levels.


Subject(s)
Cardiomyopathy, Dilated/blood , Nerve Growth Factors/blood , S100 Proteins/blood , Biomarkers/blood , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/physiopathology , Disease Progression , Echocardiography , Female , Follow-Up Studies , Humans , Immunoassay , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Prognosis , Protein Precursors , S100 Calcium Binding Protein beta Subunit , Severity of Illness Index , Stroke Volume
3.
Neurochem Res ; 32(7): 1150-5, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17401665

ABSTRACT

The participation of protein serine/threonine kinases in memory formation and retrieval is well established. In contrast, relatively little is known on the role of protein tyrosine kinases (PTKs). Previous work showed that intra-hippocampal infusion of the Src-PTK inhibitor radicicol inhibits memory acquisition, consolidation, and retrieval of one-trial step-down inhibitory avoidance task. In this study, we investigated the possible interaction between levels of Src-PTK activity in hippocampus and memory acquisition, formation, and retrieval of this task. Radicicol (0.5 microg/ml) was infused into the CA1 region of the hippocampus of rats trained in a one-trial step-down inhibitory avoidance task. Radicicol infused 15 min before training decreased Src-PTK activity, as measured 0, 1.5, and 24 h after training, and impaired memory acquisition of the task. When given immediately after training, there was a decrease in Src-PTK activity 1.5 h, but not 0 or 24 h after training. This treatment depressed memory consolidation. Radicicol infused into CA1 10 min prior to retrieval testing inhibited hippocampal Src-PTK activity, as measured immediately after the test session. The results suggest that Src-PTKs participate in memory acquisition, consolidation, and retrieval processes, but the timing of the role of the enzyme is different in each case.


Subject(s)
Avoidance Learning , Hippocampus/enzymology , Memory/physiology , src-Family Kinases/metabolism , Animals , Enzyme Inhibitors/metabolism , Macrolides/metabolism , Male , Rats , Rats, Wistar , src-Family Kinases/antagonists & inhibitors
4.
Behav Brain Res ; 162(2): 173-81, 2005 Jul 30.
Article in English | MEDLINE | ID: mdl-15970215

ABSTRACT

Although many studies have investigated the function of cellular prion protein (PrPc), its physiologic role remains elusive. PrPc null mice have been reported to develop normally and to show normal performance in most behavioural tests. In the present study we investigated whether this also holds true after episodes of acute stress. PrPc gene ablated (Prnp0/0) and wild-type mice were subjected to restraint stress, electric foot shock, or swimming and compared with non-stressed animals. Immediately after the stressful situation, the anxiety levels and locomotion of the animals were measured using plus-maze and open-field tests. Among non-stressed animals, there was no significant difference in performance between Prnp0/0 and wild type animals in either test. However, after acute stress provoked by a foot shock or a swimming trial, Prnp0/0 animals showed a significant decrease in anxiety levels when compared with control animals. Moreover, after the swimming test, knockout mice presented decreased locomotion when compared to wild-type mice. Because of this observation, we also assessed both types of mice in a forced swimming test with the objective of better evaluating muscle function and found that Prnp0/0 animals presented reduced forced swimming capacity when compared to controls. As far as we know, this is the first report suggesting that cellular prion protein is involved in modulation of anxiety or muscular activity after acute psychic or physical stress.


Subject(s)
Behavior, Animal/physiology , PrPC Proteins/deficiency , Stress, Psychological/genetics , Stress, Psychological/physiopathology , Analysis of Variance , Animals , Electroshock/methods , Exploratory Behavior/physiology , Male , Maze Learning/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Reaction Time/radiation effects , Restraint, Physical/methods , Swimming/physiology
5.
J Neurosci Res ; 79(1-2): 248-53, 2005.
Article in English | MEDLINE | ID: mdl-15558762

ABSTRACT

Oral and intraperitoneal administration of the nucleoside guanosine have been shown to prevent quinolinic acid- (QA) and alpha-dendrotoxin-induced seizures, impair memory, and impair anxiety in rats and mice. We investigated the effect of 2-weeks ad lib orally administered guanosine (0.5 mg/ml) on seizures induced by QA, inhibitory avoidance memory, and locomotor performance in rats. We also studied the mechanism of action of guanosine through the measurement of its concentration in the cerebrospinal fluid (CSF) and its effect on glutamate uptake in cortical slices of rats. QA produced seizures in 85% of rats, an effect partially prevented by guanosine (53% of seizures; P = 0.0208). Guanosine also impaired retention on the inhibitory avoidance task (P = 0.0278) and decreased locomotor activity on the open field test (P = 0.0101). The CSF guanosine concentration increased twofold in the treated group compared to that in the vehicle group (P = 0.0178). Additionally, QA promoted a 30% decrease in glutamate uptake as compared to that with intracerebroventricular saline administration, an effect prevented by guanosine in animals protected against QA-induced seizures. Altogether, these findings suggest a potential role of guanosine for treating diseases involving glutamatergic excitotoxicity such as epilepsy. These effects seem to be related to modulation of glutamate uptake.


Subject(s)
Behavior, Animal/drug effects , Glutamic Acid/metabolism , Guanosine/administration & dosage , Seizures/chemically induced , Analysis of Variance , Animals , Avoidance Learning/drug effects , Chromatography, High Pressure Liquid/methods , Drug Administration Schedule , Drug Interactions , Exploratory Behavior/drug effects , Guanosine/toxicity , Inhibition, Psychological , Male , Quinolinic Acid/toxicity , Rats , Rats, Wistar , Reaction Time/drug effects , Seizures/cerebrospinal fluid
6.
Brain Res ; 1028(2): 213-8, 2004 Dec 03.
Article in English | MEDLINE | ID: mdl-15527746

ABSTRACT

Predator stress is a type of psychogenic stress induced by an innate recognition of threat. S100B, a calcium-binding protein secreted by astrocytes, has been associated with neurotrophic or neurotoxic action in several neuropsychiatric disorders. It has been recently demonstrated that serum S100B levels in rats are increased after stress by immobilization [S. Scaccianoce, P. Del Bianco, G. Pannitteri, F. Passarelli, Relationship between stress and circulating levels of S100B protein, Brain Res. 1004 (2004) 208-11]. This study aimed to measure cerebrospinal fluid (CSF) S100B in rats after an acute stress situation, which is induced by exposure to a predator. S100B was measured in CSF and in hippocampal and cortical slices by ELISA. Forty-three male Wistar rats, aged 70 days, were randomly assigned to handled (control) or stressed groups (exposed to a cat for 5 min). CSF and brain tissue were removed 1 or 24 h after the procedures. Rats exposed to the cat demonstrated a biphasic change in CSF S100B levels. An increase was observed at 1 h after cat exposure, and a decrease was observed 24 h later, although this was not accompanied by changes in S100B content in hippocampus or cerebral cortex. The effectiveness of the stressor used was confirmed by increased freezing response (during cat exposure) and increased anxiety in the plus maze test (1 h after cat exposure). These results indicate that CSF S100B is changed by stress, reinforcing the possibility that this protein is involved in the adaptive response to stress and/or in secondary neuropsychiatric disorders.


Subject(s)
Brain Chemistry/physiology , Nerve Growth Factors/cerebrospinal fluid , Predatory Behavior , S100 Proteins/cerebrospinal fluid , Stress, Physiological/cerebrospinal fluid , Analysis of Variance , Animals , Behavior, Animal , Brain/anatomy & histology , Brain/metabolism , Cats , Enzyme-Linked Immunosorbent Assay/methods , Immobilization/methods , Male , Maze Learning/physiology , Random Allocation , Rats , S100 Calcium Binding Protein beta Subunit , Time Factors
7.
Neurobiol Learn Mem ; 81(2): 137-43, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14990233

ABSTRACT

Extracellular guanine-based purines, mainly the nucleoside guanosine, have recently been shown to exert neuroprotective effects, which seem to be related to antagonism of the glutamatergic system. In this study, we investigated the effects of acute oral administration of guanosine on inhibitory avoidance task in rats and mice. We also studied its effects on locomotor activity, anxiety-related behaviors and mechanisms of action involving the purinergic system. Guanosine (2.0 and 7.5mg/kg, per os), administered 75min pretraining, dose-dependently impaired retention of the inhibitory avoidance task in rats and mice, an effect not prevented by the adenosine receptor antagonist caffeine. Guanosine presented no effects on locomotor activity and anxiety-related behaviors. This amnesic effect of guanosine may be compatible with inhibition of glutamatergic system and seems to be not mediated by adenosine.


Subject(s)
Avoidance Learning/drug effects , Guanosine/adverse effects , Inhibition, Psychological , Maze Learning/drug effects , Administration, Oral , Animals , Behavior, Animal/drug effects , Guanosine/administration & dosage , Male , Mice , Rats , Rats, Wistar , Receptors, AMPA/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
8.
Brain Res ; 977(1): 97-102, 2003 Jul 04.
Article in English | MEDLINE | ID: mdl-12788518

ABSTRACT

Acute administration of intraperitoneal and oral guanosine has been shown to prevent quinolinic acid and alpha-dendrotoxin-induced seizures in rats and mice. In this study, we investigated the effects of 2 weeks ad libitum consumption of guanosine (0.5 mg/ml) added to mice water supply on seizures and lethality induced by the alpha-dendrotoxin, hole-board behavior, inhibitory avoidance task, locomotor activity, motor coordination, rectal temperature, body weight, and water and food consumption. Guanosine prevented seizures in 40% and death in 50% on mice treated with i.c.v. alpha-dendrotoxin; it also impaired inhibitory avoidance memory and increased head-dipping behavior and locomotor activity on the hole-board test. Guanosine consumption did not alter any of the other parameters evaluated. The anticonvulsant, amnesic, and anxyolytic-like effects may be associated with the ability of guanosine in modulating the glutamatergic excitatory system. Adding to previously reported data, these findings suggest a potential role for chronic guanosine in the management of diseases associated with glutamatergic excitotoxicity, including epilepsy and anxiety.


Subject(s)
Anticonvulsants/therapeutic use , Guanosine/therapeutic use , Seizures/prevention & control , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/therapeutic use , Anticonvulsants/administration & dosage , Anxiety/prevention & control , Behavior, Animal/drug effects , Body Temperature/drug effects , Drug Administration Routes , Drug Administration Schedule , Elapid Venoms/toxicity , Exploratory Behavior/drug effects , Guanosine/administration & dosage , Male , Mice , Motor Activity/drug effects , Neurotoxins , Reaction Time/drug effects , Seizures/chemically induced , Seizures/mortality
9.
Eur J Pharmacol ; 437(3): 151-4, 2002 Feb 22.
Article in English | MEDLINE | ID: mdl-11890903

ABSTRACT

Male Wistar rats were bilaterally implanted with indwelling cannulae in the caudal region of the posterior cingulate cortex. After recovery, animals were trained in a step-down inhibitory avoidance task (3.0-s, 0.4-mA foot shock) and received, immediately after training, a 0.5-microl infusion of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA; 1, 50 or 100 nM) or of the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 1, 25 or 50 nM). Animals were tested twice, 1.5 h and, again, 24 h after training, in order to examine the effects of these agents on short- and long-term memory, respectively. Only 50-nM DPCPX was effective in altering memory, promoting a facilitation. These results suggest that adenosine A1 receptors in the posterior cingulate cortex inhibit memory consolidation in a way that their blockade facilitates memory for inhibitory avoidance in rats.


Subject(s)
Adenosine/analogs & derivatives , Gyrus Cinguli/drug effects , Memory/drug effects , Purinergic P1 Receptor Antagonists , Xanthines/pharmacology , Adenosine/pharmacology , Animals , Avoidance Learning/drug effects , Dose-Response Relationship, Drug , Gyrus Cinguli/metabolism , Male , Rats , Receptors, Purinergic P1/physiology , Retention, Psychology/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...